Reach Us +1-947-333-4405


Single-cell Molecular Analysis Reveals A Novel Molecular Pathway In Glioblastoma | 78630
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google scholar citation report
Citations : 1147

Journal of Clinical & Experimental Pathology received 1147 citations as per google scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Single-cell molecular analysis reveals a novel molecular pathway in glioblastoma

13th European Pathology Congress

John Zhong

University of Southern California, USA

ScientificTracks Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681-C1-037

Molecular analysis has transformed pathology from the morphological age into the molecular era. This transition is similar to the transition from analog to digital TV. With molecular profiling, pathology is more precise and quantitative. However, tumor heterogeneity remains a major hurdle for obtaining the molecular profile of cancer. In this study, we apply single-cell technology to overcome this hurdle and obtain a molecular profile of a tumor stem cell from a glioblastoma multiforme (GBM) patient. We obtain the initial diagnostic biopsy from a male patient and a relapse biopsy from the same patient. We first enriched tumor stem cells by organ slide culture with the diagnosis biopsy, and then perform single-cell RNA-seq on the cultured cells (enriched for tumor stem cells). The relapse tumor is generated from the tumor stem cells which is rare in the initial (diagnosis) tumor, but becomes majority in relapse. Therefore, single-cells carrying mutations detected in the relapse biopsy but not in the diagnosis biopsy (too rare to be detected) are the tumor initiation cells (tumor stem cells). With this approach, we reveal a novel molecule pathway in the GBM involving multiple member of the P53 pathway.

John Zhong completed his BS degree in Molecular Biology at California State University, San Jose and pursuing his PhD at University of Southern California. His study is focused on Cancer Biology, specifically molecular foundation of carcinogenesis.